• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Hematology

Vaccine-induced immune thrombotic thrombocytopenia may worsen the severity of cerebral venous thrombosis

byJessie WillisandTeddy Guo
October 6, 2021
in Hematology, Infectious Disease, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The primary outcome of mortality or dependency was greater in patients with VITT-associated CVT compared to non-VITT CVT (p=0.0061).

2. Better prognosis was seen in VITT-associated CVT for patients treated with non-heparin anticoagulants (p=0.0031) and intravenous immunoglobulins (p=0.022).

Evidence Rating Level: 2 (Good)

Study Rundown: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse event thought to be associated with the receipt of adenovirus vector COVID-19 vaccines. Proposed diagnostic criteria for VITT include symptom onset 4-28 days from vaccination, low platelet count, presence of anti-PF4 antibodies, and elevated D-dimer. This study analyzed data from patients who experience cerebral venous thrombosis (CVT) following COVID-19 vaccination with the aim of better understanding VITT-associated CVT. When comparing VITT-associated CVT versus non-VITT-associated CVT, patients with VITT were more likely to die or be dependent on others following hospitalization. Patients with VITT were also more likely to have extracranial thrombosis. Further analysis performed on the VITT-associated CVT patients demonstrated better outcomes in patients treated with non-heparin anticoagulants and intravenous immunoglobulins (IVIG). Limitations of this study include the small number of patients due to the rare condition. Nevertheless, this study provides important data regarding the clinical features of VITT-associated CVT, including potential treatment strategies and recommendations to clinicians.

Click to read the study in the Lancet

Click to read an accompanying editorial in the Lancet

Relevant Reading: Prognosis of Cerebral Vein and Dural Sinus Thrombosis

RELATED REPORTS

BNT162b2 COVID-19 vaccine safe and efficacious in young children

Increased morbidity and mortality among pregnant women with Omicron-related COVID-19

COVID-19 mRNA vaccines are safe and effective in children aged 5 to 11 years

In-Depth [retrospective cohort]: In this study, cases of patients with cerebral venous thrombosis after COVID-19 vaccination were sought out via communications to physicians in the United Kingdom. Clinical and demographic data was included from 95 patients across the United Kingdom who had a CVT event after vaccination. VITT was determined by a recorded platelet count below 150×109 per L, elevated D-dimer levels (≥2000 µg/L), and the presence of anti-PF4 antibodies on ELISA. In total, of 95 patients presenting with CVT following a COVID-19 vaccination, 70 patients were met the criteria for VITT and 25 did not. Demographic differences showed that patients with VITT were generally younger than those without VITT (median age [IQR] 47 years [32-55] vs. 57 years [41-62], respectively; p=0.0045). There was no significant difference in sex of VITT between non-VITT patients.

Between patients with VITT and those without, there were a few notable differences. All VITT patients (n=70) were vaccinated with one dose of ChAdOx1 (Oxford-AstraZeneca) vaccine. In contrast, 85% of non-VITT patients (n=21) received one dose of ChAdOx1 before the CVT event, whereas the rest (n=4 [16%]) had either one or two doses of BNT162b2 (Pfizer-BioNTech). While there were no clinical differences in CVT symptomatology between the two groups, there were some notable differences in disease severity. For example, the number of veins thrombosed, intracerebral hemorrhages and venous infarctions was greater in patients with VITT. In addition patients with VITT were more likely to present with extracranial thrombosis compared.

To measure disease morbidity, the modified Rankin scale (where 0 is no symptoms, 5 is severe disability and 6 is death during admission) was used at patient discharge. The primary outcome of mortality or dependency was significantly increased in patients with VITT-associated CVT (31 of 70 patients [44%] compared to non-VITT (4 of 25 [16%]; p=0.0003). Patients with VITT had better outcomes if they were treated with non-heparin anticoagulants (p=0.0031) or IVIGs (p=0.022).

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bnt162b2cerebral venous thrombosisChAdOx1 nCoV-2 vaccineChAdOx1 vaccinecovidCOVID-19 Vaccinevaccine-induced immune thrombotic thrombocytopeniavaccine-induced immune thrombotic thrombocytopenia (VITT)
Previous Post

Prophylactic scopolamine butylbromide reduces death rattle at end of life compared to placebo

Next Post

Methylprednisolone in severe COVID-19 pneumonia associated with clinical benefit in those with high baseline serum ferritin

RelatedReports

AAP recommends disaster preparedness measures for children
Infectious Disease

BNT162b2 COVID-19 vaccine safe and efficacious in young children

February 23, 2023
Prenatal antidepressant exposure may increase risk of poor motor development
Infectious Disease

Increased morbidity and mortality among pregnant women with Omicron-related COVID-19

February 21, 2023
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

COVID-19 mRNA vaccines are safe and effective in children aged 5 to 11 years

February 8, 2023
Social networks play key roles in parental vaccination decisions
Infectious Disease

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

January 30, 2023
Next Post
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Methylprednisolone in severe COVID-19 pneumonia associated with clinical benefit in those with high baseline serum ferritin

Impairment in executive function associated with congenital heart disease in school-aged children

Coronavirus: How to avoid overeating when working from home

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Specific histopathologic renal lesions may be associated with increased risk of cardiovascular disease
  • Symptom and viral relapse more common in COVID-19 patients without antiviral treatment
  • The Scan by 2 Minute Medicine®: Endometriosis Awareness Month, OnlineMedEd Charges, Canadian Grocery Store Controversy, BetterHelp’s Privacy Concerns
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options